

ANNEX 3 – FACTSHEET

MEMORANDUM OF UNDERSTANDING BETWEEN SCRI AND ONCOSHOT TO ENHANCE CLINICAL TRIAL INITIATION, SCREENING AND ENROLMENT

The Singapore Clinical Research Institute (SCRI) has signed a memorandum of understanding (MOU) with local health-tech company Oncoshot to leverage its technology which has the potential to significantly enhance the initiation, screening, and enrolment of patients into oncology trials.

As part of the MOU, SCRI will collaborate with Oncoshot on Project EISE (Enhanced Clinical Trial Initiation, Screening and Enrolment; pronounced “easy”), Singapore's first nationwide collaboration that connects cancer patients, public and private healthcare professionals, and pharmaceutical and biotechnology companies in one ecosystem.

This partnership addresses two key challenges in clinical trial screening and enrolment for public healthcare institutions (PHIs):

1. **Providing PHI clinical trial Investigators with access to a larger cross-institutional patient pool for oncology trials**

Currently, PHI clinical trial investigators wishing to conduct trials on promising cancer treatments are limited to the patient pool of their affiliated cancer institutes. If there are insufficient subjects for their clinical trials, these investigators may not know which other cancer centres to approach for access to more patients.

Through SCRI, public healthcare investigators can now access information regarding the oncology patient populations in Oncoshot's network of public and private healthcare institutes. This includes public entities such as the National Cancer Centre Singapore and Tan Tock Seng Hospital, as well as private entities such as Curie Oncology and ICON Cancer Centre; and other leading Australian data partners.

Improving access to larger patient populations will enhance and accelerate recruitment for oncology trials conducted in Singapore while making it easier for patients to reach developmental therapies.

2. Providing clinical trial investigators with a platform to find suitable patients for their trials

The process of screening patients for cancer clinical trials is presently a lengthy, cumbersome, and manual one. It involves a detailed review of individual patient records to determine if they match highly specific trial criteria. The local institutes' patient databases may also lack annotated biomarker information that would otherwise allow trial investigators to select suitable patients for these treatments.

Through this partnership, SCRI now offers PHI investigators access to aggregated insights based on anonymised, well-annotated, and up-to-date patient data from across Oncoshot's network of public and private cancer institutes. SCRI will be able to perform feasibility assessments for investigators to determine if there is a sufficiently sized eligible patient pool to initiate a new trial.

About Oncoshot

Oncoshot was founded in 2018 to help oncologists identify cancer clinical trials more efficiently and effectively for patients and their caregivers by supporting hospitals and research partners. In today's fast-changing landscape of cancer care, Oncoshot's focus is to leverage technology to address the inefficiencies of cancer clinical trials.

With its secure health insights exchange platform, the company aims to accelerate enrolment into cancer clinical trials by building a bridge between leading regional healthcare institutions and contract research organisations and global biotechnology and pharmaceutical companies.

For more information, please visit <https://www.oncoshot.com>